Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$45.65M

FY 2025 · Annual

Investing Cash Flow

$4.56M

FY 2025 · Annual

Financing Cash Flow

$275,000.00

FY 2025 · Annual

-99.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Depreciation & Amortization0130K000
Deferred Income Tax00000
Stock-Based Compensation1.9M1.88M4.99M5.29M6.45M
Change in Working Capital(55K)4.21M(978K)(1.05M)(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables00120K(907K)929K
Other Working Capital(55K)4.21M(1.1M)(141K)(1.98M)
Other Non-Cash Items883K(215K)98K(1.11M)(8K)
Operating Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments0(41.45M)(19.62M)(108.09M)(106.86M)
Sales of Investments09.44M32.2M46.4M111.42M
Other Investing Activities00000
Investing Cash Flow0(32.01M)12.58M(61.68M)4.56M
Debt Repayment00000
Common Stock Issued012K89.68M105.75M275K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.07M)(85K)(3.51M)(931K)0
Financing Cash Flow9.74M(73K)86.17M104.82M275K
Effect of Forex Changes00000
Net Change in Cash(11.97M)(56.57M)74.98M701K(40.82M)
Free Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$51.0M
+ D&A$0
+ Stock-Based Comp$6.4M
+ Deferred Tax$0
- Working Capital-$1.1M
- Other Non-Cash-$8.0K
= Operating Cash Flow-$45.6M
- Capex$0
= Free Cash Flow-$45.6M

Analysis

FY2025 free cash flow is -$45.6M. FCF conversion is 89.4% of net income. Operating cash flow was -$45.6M, with capex of $0. The largest bridge item is Stock-Based Comp at $6.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
8-KCurrent reportOct 22, 2026
SC 13GSC 13G filingOct 7, 2026

Does SGMT generate free cash flow?

Sagimet Biosciences Inc. (SGMT) generated -$45.65M of free cash flow in fiscal 2025.

How much operating cash flow does SGMT produce?

Operating cash flow was -$45.65M, before capital expenditures of $0.00.